Names and pronunciation
(fen′ter-meen/toe-pyre′a-mate) Qsymia
PDF page 1046
Loading InternPractice…
Drug reference
(fen′ter-meen/toe-pyre′a-mate) Qsymia
PDF page 1046
Func. class.: Anorexiant/anticonvulsant Controlled Substance: Schedule IV
PDF page 1046
USES: Adjunct to a reduced-calorie diet and increased physical activity, in patients with either an initial body mass index (BMI) of ≥30 kg/m2 or an initial BMI of ≥27 kg/m2 and at least one weight-related comorbid condition (HTN, dyslipidemia, type 2 diabetes)
PDF page 1046
CONTRAINDICATIONS Hypersensitivity to phentermine, other sympathomimetic amines, CV (arrhyth- mias, HF, CAD, uncontrolled HTN); hyperthyroidism; glaucoma; agitation; use within 14 days of MAOIs; pregnancy; breastfeeding
PDF page 1046
Black Box Warning: Substance abuse
PDF page 1046
DOSAGE AND ROUTES Weight management Adult: PO Initial: Phentermine 3.75 mg/ topiramate 23 mg daily × 14 days; increase to phentermine 7.5 mg/topira- mate 46 mg daily × 12 wk then evaluate, if 3% of body weight has not been lost, dis- continue use or increase dose to phenter- mine 11.25 mg/topiramate 69 mg daily × 14 days, then to phentermine 15 mg/topi- ramate 92 mg daily, evaluate weight loss after 12 wk on phentermine 15 mg/ topiramate 92 mg; if 5% of body weight has not been lost at phentermine 15 mg/ topiramate 92 mg gradually discontinue therapy 1 dose every other day for ≥ 1 wk
PDF page 1046
Available forms: Capsule 3.75/23, 7.5/46, 11.25/69, 15 mg/92 mg HIGH ALERT
PDF page 1046